Either ellagic acid inhibition or shRNA knockdown of LOXL2 was sufficient to decrease tumor collagen deposition and metastasis as previously observed31, but primary tumor growth was reduced only when LOXL2 suppression was combined with PD-L1 blockade and was even able to do so when administered late in the course of tumor growth when tumors had reached ~200 mm3 (Fig. 3a and b, Supplementary Fig. 5a and b). The gene discussed is LOXL2; the disease is neoplasm.